St. Jude defends Durata amid FDA warning at manufacturing facility

Thu, 01/10/2013 - 10:27am
Mass Device

St. Jude Medical CEO Daniel Starks says the FDA's warnings of manufacturing deficiencies at a California plant are unrelated to the safety and reliability of the Durata defibrillator leads that are made there.

St. Jude Medical CEO Daniel Starks

St. Jude Medical's (NYSE:STJ) implanted cardiac device market share is in great shape despite ongoing issues with its high-voltage defibrillator leads, CEO Daniel Starks told an audience at the J.P. Morgan healthcare conference last night.

Starks spent a substantial portion his presentation and the subsequent breakout session explaining why the Durata line was a sure thing, and why the Riata lead recall and FDA warnings related to a St. Jude manufacturing plant were no threat to the company's hold on the larger ICD market.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.